- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: 11F8 | IMC-11F8 | LY3012211 | Portrazza®
necitumumab is an approved drug (FDA (2015), EMA (2016))
Compound class: Antibody
Comment: Necitumumab is a monoclonal antibody with clinical antineoplastic action [1-3].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Necitumumab is being investigated in several clinical trials at various stages of development: solid tumours (Phase 1), metastatic colorectal cancer (Phase 2) and non-small-cell lung cancer (Phase 3, NCT00981058, for squamous cell NSCLC and NCT00982111, for nonsquamous NSCLC). Click here to link to ClinicalTrials.gov's complete listing of registered necitumumab trials.
In November 2015, the US FDA approved necitumumab (in combination with the chemotherapeutics gemcitabine and cisplatin) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received anti-lung cancer therapy.
|Mechanism Of Action and Pharmacodynamic Effects|
|Necitumumab targets the epidermal growth factor receptor (EGFR), inhibiting the receptor's tyrosine kinase activity and inhibiting growth of EGFR-expressing tumour cells .|
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)